Posted in

Bridging the Gap: Why Rabies Immunoglobulin is Scarce in India

•Posted inMedical Updates
Doctor reviewing career roadmap to become a neurologist after MBBS, comparing neurology training and specialisation pathways

Ensuring timely and effective treatment for rabies is crucial, particularly in a country like India where animal bites are common. A recent nationwide survey has brought to light significant concerns regarding rabies immunoglobulin availability (RIG) at public health facilities. While anti-rabies vaccines (ARVs) are mostly accessible, the scarcity of RIG poses a considerable challenge to complete post-exposure prophylaxis (PEP).

Understanding Rabies Prophylaxis: ARV vs. RIG

Rabies, a deadly viral infection, spreads through the saliva of infected animals, often dogs. Post-exposure prophylaxis is the only way to prevent the disease once symptoms appear. This comprehensive treatment includes immediate wound washing, anti-rabies vaccine administration, and, for severe bites, rabies immunoglobulin infiltration. ARV stimulates the body’s immune system to produce antibodies, providing long-term immunity. Conversely, RIG contains pre-formed antibodies, offering immediate protection against the virus. Therefore, both are vital for preventing rabies fatalities.

Concerning Survey Findings on Rabies Immunoglobulin Availability

The Indian Council of Medical Research (ICMR), along with other medical institutions, conducted a survey across 534 health facilities in 60 districts across 15 Indian states. Their findings, published in The Lancet Regional Health – Southeast Asia, revealed a notable disparity in biological availability. Specifically, ARV was available in nearly 80% of public health facilities. However, only 20% of these facilities stocked rabies immunoglobulin. This stark difference indicates a critical gap in the comprehensive management of animal bite cases.

Geographic and Facility-Level Disparities

Access to these life-saving biologicals varies significantly across India. Secondary and tertiary care centers generally show better preparedness regarding ARV availability. Yet, primary healthcare facilities often face persistent shortfalls. Furthermore, certain geographies, like the eastern and northeastern states, demonstrate lower access levels to both ARV and RIG. This uneven distribution undermines India’s national goal of eliminating dog-mediated human rabies deaths by 2030.

Cost Implications for Patients

Both ARV and RIG are provided free of cost at most public health facilities in India. Conversely, private facilities charge substantial amounts for these treatments. Patients may pay between ₹300 and ₹600 per dose for ARV and significantly more, between ₹3,000 and ₹6,000 per dose, for RIG. This cost burden can deter patients from seeking complete, timely post-exposure prophylaxis, particularly for category III bites requiring RIG.

National Efforts and Recommendations

India’s National Rabies Control Programme (NRCP) aims to eliminate dog-mediated human rabies by 2030. Achieving this target requires ensuring equitable access to affordable rabies biologicals, including rabies immunoglobulin availability. Experts recommend revisiting and realigning funding priorities to address these inequities. The study also calls for making RIG readily available at primary health care facilities alongside ARV. Additionally, including Rabies Monoclonal Antibodies (RmAbs) in national guidelines is being considered for their potential scalability and cost-effectiveness. For a deeper understanding of infectious disease management and public health strategies, consider exploring OC Academy’s Postgraduate Diploma in Infectious Disease.

Frequently Asked Questions

Q1: What is the primary difference between ARV and RIG?

ARV (Anti-Rabies Vaccine) stimulates the body’s immune system to produce its own antibodies, providing long-term protection. On the other hand, RIG (Rabies Immunoglobulin) contains pre-formed antibodies, offering immediate, short-term protection against the rabies virus, crucial for severe bite cases.

Q2: Why is rabies immunoglobulin availability a concern in India?

A recent ICMR survey revealed that while ARVs are available in nearly 80% of public health facilities, RIG is present in only 20%. This significant gap affects the complete and timely post-exposure prophylaxis, especially for severe animal bites, hindering India’s rabies elimination goal.

Q3: Are anti-rabies treatments expensive in India?

In public health facilities, both ARV and RIG are generally provided free of cost. However, private facilities charge for these treatments. ARV doses can range from ₹300 to ₹600, while RIG doses are considerably more expensive, ranging from ₹3,000 to ₹6,000.

References

  1. RIG availability at public health facilities is a concern: Survey – ETHealthworld.
  2. Uneven access to rabies care: survey flags gaps in vaccine and immunoglobulin availability in India – The Hindu.
  3. Availability of anti-rabies vaccine and rabies immunoglobulin in Indian health facilities: a nationwide cross-sectional health facility survey – PubMed.
  4. National Guidelines for Rabies Prophylaxis in India | PPTX – SlideShare.
  5. Rabies management pointers for Indian doctors – M3 India.
  6. Study Finds Major Gaps Across India’s Rabies Vaccine Availability – Health Dialogues.
  7. (PDF) Availability of anti-rabies vaccine and rabies immunoglobulin in Indian health facilities: a nationwide cross-sectional health facility survey – ResearchGate.
  8. National Guidelines for Rabies Prophylaxis 2019.
  9. India aims to eliminate rabies by 2030: Study – The Tribune.
  10. Rabies Vaccination – Immunize India.
  11. National Guidelines for Rabies Prophylaxis and Intra-dermal Administration of Cell Culture Rabies Vaccines.
  12. Assessment of Procurement, Distribution, Availability, and Utilization of Rabies Biologicals for Postexposure Prophylaxis in Sev – Apcri.
  13. GOVERNMENT OF INDIA MINISTRY OF HEALTH AND FAMILY WELFARE DEPARTMENT OF HEALTH AND FAMILY WELFARE RAJYA SABHA UNSTARRED QUESTION.

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.